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Abstract: Debate persists around the risk–benefit balance of vaccinating adolescents and children
against COVID-19. Central to this debate is quantifying the contribution of adolescents and children
to the transmission of SARS-CoV-2, and the potential impact of vaccinating these age groups. In
this study, we present a novel SEIR mathematical disease transmission model that quantifies the
impact of different vaccination strategies on population-level SARS-CoV-2 infections and clinical
outcomes. The model employs both age- and time-dependent social mixing patterns to capture the
impact of changes in restrictions. The model was used to assess the impact of vaccinating adolescents
and children on the natural history of the COVID-19 pandemic across all age groups, using the
UK as an example. The base case model demonstrates significant increases in COVID-19 disease
burden in the UK following a relaxation of restrictions, if vaccines are limited to those ≥18 years and
vulnerable adolescents (≥12 years). Including adolescents and children in the vaccination program
could reduce overall COVID-related mortality by 57%, and reduce cases of long COVID by 75%. This
study demonstrates that vaccinating adolescents and children has the potential to play a vital role in
reducing SARS-CoV-2 infections, and subsequent COVID-19 morbidity and mortality, across all ages.
Our results have major global public health implications and provide valuable information to inform
a potential pandemic exit strategy.
Keywords: adolescent; coronavirus; disease transmission model; COVID-19; SARS-CoV-2; vaccination
1. Introduction
The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has resulted in more than 193 million confirmed cases of
COVID-19 and more than 4 million deaths globally, as of 26 July 2021 [1]. It has been
estimated that at least one in five people infected with COVID-19 experience persistent
ill health following the acute phase of infection. This condition is typically referred to as
long COVID; it includes both ongoing symptomatic COVID-19, with signs and symptoms
continuing for 4 to 12 weeks after acute COVID-19, as well as post-COVID-19 syndrome,
with signs and symptoms that develop during or after acute COVID-19 continuing for
more than 12 weeks, and which cannot be explained by an alternative diagnosis [2].
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Vaccinations against SARS-CoV-2 reduce serious illness and transmission, thereby
limiting the health and socioeconomic impacts of the pandemic. The global rollout of
vaccines to adults is proceeding apace, with the World Health Organization (WHO) re-
porting that 3.6 billion vaccine doses have been administered as of 25 July 2021 [1]. The
success of vaccination programs depends upon multiple factors, including vaccine efficacy,
the speed of vaccine rollout and uptake rates, the emergence of new variants, patterns
of social mixing and, critically, population vaccination strategies. In countries where an
increasing percentage of adults are fully vaccinated, but where children and adolescents are
not, debate persists as to the population relevance of the high prevalence of SARS-CoV-2 in
children and adolescents, and the role of vaccinating younger age groups in controlling the
pandemic. In the UK, vaccination of those over the age of 12 years is, as of 30 July 2021,
limited to vulnerable individuals and those in households with immunocompromised
members; mass vaccination of children and adolescents is not currently planned [3].
Currently, the AstraZeneca (Oxford), BioNTech/Pfizer, and Moderna COVID-19 vac-
cines are available across the UK, all of which provide effective protection against coro-
navirus infection, and even better protection against serious illness and disease. There
has been a small number of cases of severe side-effects and deaths among those receiving
the AstraZeneca vaccine. However, for people aged 30 years or over and those with other
health conditions, the benefits of being vaccinated outweigh any risk associated with this
vaccine. For people aged under 30 years and without other health conditions, it is advised
that they receive an mRNA vaccine from Pfizer/BioNTech or Moderna as an alternative
to this vaccine. The efficacy and safety of these mRNA vaccines in those under 18 years
of age has recently been evaluated, with both Pfizer/BioNTech’s BNT162b2 vaccine and
Moderna’s mRNA-1273 vaccine demonstrating 100% vaccine efficacy in phase 3 trials of
adolescents, and with only mild side effects, generally consistent with those observed in
individuals ≥18 years [4,5]. Based on these results, Pfizer/BioNTech’s vaccine has been
approved for adolescents ≥12 years in the US, as well as in European Union member
states and in the UK [6–8]. Moreover, the European Medicines Agency’s (EMA) Committee
for Medicinal Products for Human Use (CHMP) has recently adopted a positive opinion,
recommending marketing authorization for Moderna’s vaccine to include adolescents
≥12 years [9], with other nations following suit.
Given uncertainty regarding the potential benefit of vaccinating adolescents and
children, coupled with the economic pressure to relax population restrictions globally,
there is a pressing need to evaluate the public health impact of vaccinating individuals
<18 years old. In recent years, our understanding of infectious disease epidemiology has
been greatly increased through mathematical models, which have generated quantitative
information to inform public health planning and infectious disease control [10–12]. Such
mathematical models have become a central tool in the control of COVID-19 in many
countries; they can provide short- and long-term forecasts regarding the future direction of
the COVID-19 pandemic, and provide a framework for evaluating the potential impact
of different vaccination strategies. The most relevant mathematical models relating to the
spread of a pandemic are compartmental models, with the population divided into different
population groups based on their infection status (e.g., susceptible, exposed, infectious,
recovered), and with assumptions being made about the rate of transfer from one group
to another. Here, we use a novel Susceptible-Exposed-Infectious-Recovered (SEIR) model
to quantify the impact of COVID-19 variants on disease and transmission, using the UK
as an example due to the country’s high COVID-19 vaccination rates in adults, the high
prevalence of the delta variant, and the lifting of all COVID-19 restrictions as of 19 July
2021. We evaluated the impact of returning to pre-pandemic levels of social mixing in the
UK from 19 July 2021 on future COVID-19 pandemic dynamics. In addition, we assessed
the population level impact of extending the vaccination program to all adolescents, as well
as to all adolescents and children, on SARS-CoV-2 infection rates, hospitalization, mortality,
and rates of long COVID.
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2. Methods
2.1. Disease Transmission Model Overview
We developed an age-stratified, deterministic SEIR compartmental model of SARS-
CoV-2 infections (Figure 1), structured to evaluate transmission within nine incremental
age bands of 10 years each, from 0 years old to 79 years old, and an additional age group
comprising those 80+ years old.
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Figure 1. Flow diagram characterizing the transmission model.
In the model, the uninfected population originates in the ‘susceptible (S)’ state and
progresses through epidemiological stages once infected. Once exposed to the virus,
transition from the ‘susceptible’ state to the ‘exposed (E)’ state occurs, where the infection
is latent and not yet infectious (the ‘incubation period’). Subsequently, the infected may
develop symptoms (although a large proportion will remain asymptomatic) and transition
to the ‘infectious (I)’ state. Those within the infectious state may either transition to the
‘recovered (R)’ state once the infection has abated, or develop severe disease, requiring
hospitalization (H) and possibly admission to an intensive care unit (ICU). Furthermore, a
proportion of infected individuals may develop long COVID (LC). Age-dependent rates
are utilized to model the incidence of long COVID, hospitalization, and mortality (either
within the community or in hospital). Those critically ill patients may recover, or they may
die due to COVID-19.
We used this model to characterize the SARS-CoV-2 infection dynamics from the
beginning of the UK epidemic to validate the model’s capacity to extrapolate beyond
the present day. The model captures the impact of restrictions, such as lockdown and
social distancing, using age-dependent and calendar time-dependent contact matrices.
Therefore, the model can predict short-term infection dynamics and assess any policy
changes regarding epidemic management. It can further predict the impact if the UK
were to expand the vaccination program to include adolescents (≥12 years) and children
(≥5 years) using an mRNA vaccine. A full description of the parameters and assumptions
in the model are provided in the supplementary appendix (Supplementary Methods,
Tables S1–S9, Figures S1 and S2).
2.2. Scenarios Evaluated
The Base Case (BC) follows current UK guidance, using vaccine coverage projections
for adults ≥ 18 years and adoles ents aged ≥12 years at increased risk f serious COVID-19
disease and hospitalization. We assume that this represe ts pproximately 370,000 adoles-
cents of 12–17 years who are classified as vulnerable, and that coverage will be 1 % in
this vulnerable group, representing an optimistic scenario.
The Base Case plus Adolescents (BCA) scenario is as per the BC scenario but extended
to assume vaccine coverage in 12–17-year-olds is 100%, representing an optimistic scenario
(and with alternative scenarios explored in sensitivity analysis). The 2019, mid-year
estimates for the UK calculate the population of 12–17-year-olds as 4.5 million (4,482,216).
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The Base Case, Adolescents and Children (BCAC) scenario is as per the BCA scenario
but extended to assume all children 5–11 years old are vaccinated (approximately an
additional 4.1 million (4,149,852) children).
Tables S10–S12 and Figures S3–S5 illustrate the vaccine coverage and rate of uptake
applied for each scenario: BC, BCA, and BCAC, respectively.
2.3. Sensitivity Analysis
For the three scenarios outlined above, we assumed that the effective reproductive
number (Reff), defined as the number of secondary infections produced by a single in-
fectious individual when the population has both susceptible and non-susceptible (e.g.,
infectious, immune, vaccinated) individuals, and/or interventions are in place to combat
the spread of infection, remains at 1.4 until 31 December 2021. This is based on the assump-
tion that the voluntary use of masks and social distancing indoors is maintained, and that
the delta variant remains the dominant strain, with no new variants emerging. Scenarios
for Reff 1.7 (the highest seen in the UK during the second wave) and Reff 2.1 (estimated
value from the Netherlands two weeks after lifting restrictions) were also explored. In
addition, we assessed scenarios when we assumed that maximum vaccine coverage in
adolescents and children could be either 50% or 75%.
3. Results
Under BC settings, we estimated a further 3.8 million SARS-CoV-2 infections in the
UK between July and December 2021. Assuming no change in vaccination strategy or
social distancing measures, daily SARS-CoV-2 infections would approach approximately
300,000 per day, with daily hospitalizations and deaths approaching 1400 and 150, respec-
tively (Figure 2).
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Figure 2. Expected total (A) SARS-CoV-2 infections, (B) COVID-19 hospitalizations, (C) long COVID, and (D) COVID-19
deaths between July and December 2021 by vaccination scenario. Note: projections in panels (A,B,D) are expected versus
observed data.
This would be expected to result in a total of approximately 129,000 additional hospital
admissions and 13,000 excess deaths (Table 1). Extending vaccinations to also include ado-
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lescents and children would be expected to reduce SARS-CoV-2 infections to approximately
2 million (26% reduction) and 736,000 (64% reduction), respectively, over the same period.
Hospital admissions and deaths would decrease to approximately 101,000 (21% reduction)
and 10,500 (18% reduction), respectively, (BCA), and to 51,000 (60% reduction) and 5500
(57% reduction), respectively, (BCAC). An additional 80,000 cases of long COVID would be
expected to occur between July to December 2021, with the potential to be reduced to 58,000
(27% reduction) and 20,000 (75% reduction) when extending vaccination to adolescents
and children, respectively.
Table 1. Summary of projected cumulative infections, hospitalizations, deaths, and long COVID cases in the UK between
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1.7 2,228,161 124,566 13,296 60,579
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Bold represents the main analysis, whereas the other rows are other scenarios explored in the sensitivity analysis.
With the existing vaccination strategy (BC), approximately 60% of new infections
would be in those <18 years, with these individuals accounting for 14% of hospital admis-
sions, 61% of long COVID cases, and 0.2% deaths (Figure 3). While the mortality rate in
children <18 years is low (20 cases would be expected under the base case scenario), the
BCAC vaccination strategy would be expected to reduce overall COVID-related mortality
by 57%.
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long COVID cases (approximately 40,000), and older people (>60 years) having fewer
deaths (approximately 4000). The pattern of hospitalizations avoided is also noteworthy,
with adolescent vaccination contributing to a reduction of approximately 5700 events in
the age group, which, in absolute terms, is greater than any single adult age group.




Figure 4. Expected events avoided (absolute numbers) between July and December 2021 by extend-
ing vaccination to (A) adolescents (BCA) and (B) adolescents and children (BCAC). 
4. Discussion 
By extending the existing UK vaccination program to all adolescents ≥12 years, our 
model has demonstrated a potential 21% reduction in hospitalization due to COVID, an 
18% reduction in COVID-related deaths, and a 27% reduction in the prevalence of long 
COVID. If the vaccination schedule could be further extended to children ≥5 years, this 
benefit would be expanded to a 60% reduction in hospitalizations, a 57% reduction in 
mortality, and a 75% reduction in cases of long COVID. However, it is important to 
acknowledge that most of this direct benefit is not realized in adolescents and children 
receiving the vaccine, but largely in older individuals.  
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firmed COVID-19 contact [14]. This break in the viral transmission at schools among un-
vaccinated adolescents mimics our modelling of the impact from vaccinating this popula-
tion, without adolescents and children missing their vital educational experience. Addi-
tionally, it highlights that, once children return to school, if a viral reservoir remains in 
the community, then there is likely to be an additional, larger wave of COVID-19 cases; 
this demonstrates the need to take a population-based approach to COVID-19 manage-
ment. Our study demonstrates that this burden can be reduced by 35% if the current UK 
vaccination program is extended to all adolescents ≥12 years. These results align with 
those from a recent Australian modelling study, which evaluated the impact of SARS-
CoV-2 vaccination under a range of coverage levels, vaccine efficacies, and age-groups, 
and which demonstrated that a high vaccination coverage of 90% in both adults and ado-
lescents was required to mitigate COVID-19 transmission without implementing lock-
down measures [15]. Furthermore, a study of SARS-CoV-2 vaccination in Israel provide 
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Sensitivity analyses demonstrate that an increasing Reff has a substantial impact
upon the burden of SARS-CoV-2 infections. Under the BC scenario, infections would be
expected to increase from 2.7 million to 7.4 million and 19.0 million for Reff 1.4, 1.7, and 2.1,
respectively. These additional infections would be associated with a corresponding increase
in hospitalizations, deaths, and long COVID cases (Table 1). Furthermore, sensitivity
analyses also highlight the impact associated with reduced vaccine coverage. Under the
BC scenario, infections would be expected to increase from 2.7 million to 3.0 million and
3.1 million for vaccine coverage of 100%, 75%, and 50%, respectively. These additional
infections would be associated with a corresponding increase in hospitalizations, deaths,
and long COVID cases (Table 1).
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4. Discussion
By extending the existing UK vaccination program to all adolescents ≥12 years, our
model has demonstrated a potential 21% reduction in hospitalization due to COVID, an 18%
reduction in COVID-related deaths, and a 27% reduction in the prevalence of long COVID.
If the vaccination schedule could be further extended to children ≥5 years, this benefit
would be expanded to a 60% reduction in hospitalizations, a 57% reduction in mortality,
and a 75% reduction in cases of long COVID. However, it is important to acknowledge that
most of this direct benefit is not realized in adolescents and children receiving the vaccine,
but largely in older individuals.
England lifted its coronavirus restrictions on 19 July 2021, branded ‘Freedom Day’,
despite a high community prevalence of SARS-CoV-2. More than 100 experts signed an
open letter to the UK government suggesting that ending the pandemic requires enough of
the population to be immune to prevent exponential growth of the virus, and population
immunity is unlikely to be achieved without much higher levels of vaccination across all
age-groups, and to include adolescents and children [13]. Our model supports the asser-
tions of these experts, and demonstrates a significant, expected increase in the COVID-19
disease burden over the coming months as the population moves towards pre-pandemic
levels of social mixing. However, despite the lifting of restrictions, reported cases in the UK
fell in late July/early August. This observation has been postulated to be due to a variety
of factors: the success of vaccines and NHS test-and-trace processes, a reduction in testing,
a continuation of the vast majority of individuals maintaining social distancing and face
coverings despite legislative changes, or the natural transmission break that occurred as
adolescents and children entered summer vacation. For the two weeks prior to ‘Freedom
Day’, up to 10% of adolescents and children were absent from school after confirmed
COVID-19 contact [14]. This break in the viral transmission at schools among unvaccinated
adolescents mimics our modelling of the impact from vaccinating this population, without
adolescents and children missing their vital educational experience. Additionally, it high-
lights that, once children return to school, if a viral reservoir remains in the community,
then there is likely to be an additional, larger wave of COVID-19 cases; this demonstrates
the need to take a population-based approach to COVID-19 management. Our study
demonstrates that this burden can be reduced by 35% if the current UK vaccination pro-
gram is extended to all adolescents ≥12 years. These results align with those from a recent
Australian modelling study, which evaluated the impact of SARS-CoV-2 vaccination under
a range of coverage levels, vaccine efficacies, and age-groups, and which demonstrated that
a high vaccination coverage of 90% in both adults and adolescents was required to mitigate
COVID-19 transmission without implementing lockdown measures [15]. Furthermore, a
study of SARS-CoV-2 vaccination in Israel provide observational evidence that, as well as
protecting individuals who have been vaccinated, COVID-19 vaccination provided indirect
protection to unvaccinated individuals; for every 20% point increase in the proportion of
individuals who were vaccinated, the positive test fraction for the unvaccinated population
decreased approximately two-fold [16].
Although COVID-19 illness is generally milder in children when compared with
adults, with low risks of hospitalization and death [17–19], a small number of chil-
dren present with a multisystem inflammatory state with an associated mortality rate of
1–2% [20–22]. Furthermore, evidence is emerging that children may experience long
COVID symptoms, similar to adults, which can lead to high morbidity and limitations
in daily functioning [23–25]. In adults, there is clear evidence of post-COVID damage to
the lung, heart, kidneys, and brain. The ONS reported that 15% of young adults aged
16–29 years experience long COVID symptoms, with at least 35% reporting it affecting
their work or education beyond 3 months [26]. It would be unlikely if this did not extend,
to some degree, to lower age groups. Additionally, adolescents and children are affected
by the indirect effects of COVID-19, for example, the interruption of schooling, the impact
on mental health, increased social inequalities, and in a worst-case scenario, the loss of a
parent or grandparent [27].
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The benefits of vaccinating younger individuals are only relevant if they outweigh
potential complications of vaccination. To date, the only significant adverse effect of
mRNA vaccines being explored is the risk of myocarditis and pericarditis. There have been
1226 cases reported in around 300 million doses of either the Pfizer/BioNTech or Moderna
vaccinations up to 11 June 2021, with a significant proportion occurring in adolescents (and
predominantly male adolescents), more than any other age group [28]. However, there
have been no recorded deaths due to myocarditis and pericarditis, and almost all cases have
made a spontaneous, complete recovery. Even if we were to assume a doubling of risk in
adolescents compared to adults >20 years (8 per million), extrapolation onto the adolescent
population results in 37 excess cases in the UK (which would resolve spontaneously),
compared to the several thousand hospitalizations and 23 deaths of adolescents prevented
by vaccination.
Currently there is no full authorization for children <12 years old, although the
data from two mRNA vaccines have been used to grant provisional authorization for the
Moderna and Pfizer vaccines [29,30]. Assuming these trials report no unexpected adverse
events, our model predicts a greater population-wide benefit by extending the vaccination
program to children than was observed in adolescents. Given the increased mixing patterns,
the difficulties in maintaining physical distance, and the poor adherence to face coverings,
this approach has double the impact of vaccinating those over the age of 12 (73% vs. 26%,
respectively). This benefit translates into a 75% reduction in long COVID, a condition that
we do not yet fully understand the longer-term impact of.
Limitations
This analysis assumes no further waning of vaccine efficacy over the duration of the
study, whether this be time-dependent or based on further mutations of the virus. These
assumptions, however, underestimate the potential impact of vaccinating the adolescent
population given that the risk of severe infection in fully vaccinated adults will be greater.
Similarly, the assumption that those who have previously been exposed and have recovered
are no longer susceptible has recently been challenged, with a growing number of cases of
the delta variant infecting people who have recovered from previous variants. Our model
assumed that those of the UK population (approximately 10%) that have previously had
confirmed COVID-19 were immune to further infection. This assumption, however, would
underestimate the projections for cases and have little impact on the percentage reduction
by vaccinating the adolescent population, given the very low incidence in this population.
Further, we have not specifically modelled the impact on vulnerable populations. However,
the data that were incorporated into the models did not stratify by vulnerability, but
by age alone. Clearly, within each age range there will be sub-groups at greater risk,
however this risk variability is a component of the data entered into the model and
therefore can be reasonably applied to the outputs to determine those at personal, higher
risk. Additionally, we modelled several different scenarios based around the population’s
behavioral responses to the easing of mandated restrictions. When considering the impact
of Reff rising to 1.7 or 2.1, which both have precedents in western Europe, we see a robust
percentage reduction in cases and hospitalizations, although the absolute numbers could
be higher. Regarding hospitalizations, the UK model offers high-quality, centrally funded
health care; outcomes may well be poorer in funding-constrained regions. Further, our
conclusions may not extend to regions with very different social mixing patterns. Finally,
we have not incorporated the seasonal effects on infection. Much of our knowledge
regarding the delta variant has come from public health figures in the UK since April 2021.
It is difficult to anticipate the impact of the autumn and winter on the virus. Again, this is
likely to underestimate the potential impact of vaccinating adolescents, as indoor mixing,
and therefore transmission, will be greater in winter.
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5. Conclusions
The primary aim of the global vaccination program has always been to prevent COVID-
related hospitalizations and deaths, and the data presented here clearly demonstrate that
vaccinating adolescents and children has the potential to play a vital role in achieving this
and in ending the pandemic more quickly. Indeed, a 60% reduction in hospitalizations and
a 57% reduction in mortality could potentially bring the pandemic to an end without the
need for further lockdowns or restrictions in movement. Not vaccinating adolescents and,
when the technology is licensed, children, will make it substantially more difficult for the
UK and other countries to reach the population immunity level needed to suppress the
surging delta variant and reduce circulation of SARS-CoV-2.
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